Summary
Combined empagliflozin and linagliptin as add-on therapy to metformin provided enhanced glucose-reducing efficacy when compared with either drug as monotherapy in individuals with type 2 diabetes mellitus, as discussed in this article.
- Hyperglycemia/Hypoglycemia
- Diabetes & Endocrinology Clinical Trials
- Diabetes Mellitus
- Hyperglycemia/Hypoglycemia
- Endocrinology
- Diabetes & Metabolic Syndrome
- Diabetes & Endocrinology Clinical Trials
- Diabetes Mellitus
- © 2014 MD Conference Express®
Tools
Combining Empagliflozin and Linagliptin with Metformin Reduces HbA1c in Patients with T2DM
Permalink:
Table of contents
Cited By...
- No citing articles found.